In CLL it has been reported that targeting cell adhesion sensitized leukemic cells to chemotherapeutics and inhibition of PKC or PI3K overcome the stroma-induced resistance [53]. The gene discussed is PRRT2; the disease is B-cell chronic lymphocytic leukemia.